GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » FSD Pharma Inc (NAS:HUGE) » Definitions » Additional Paid-In Capital

FSD Pharma (FSD Pharma) Additional Paid-In Capital : $30.23 Mil(As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is FSD Pharma Additional Paid-In Capital?


FSD Pharma's quarterly additional paid-in capital increased from Jun. 2023 ($29.83 Mil) to Sep. 2023 ($30.20 Mil) and increased from Sep. 2023 ($30.20 Mil) to Dec. 2023 ($30.23 Mil).

FSD Pharma's annual additional paid-in capital increased from Dec. 2021 ($22.58 Mil) to Dec. 2022 ($28.50 Mil) and increased from Dec. 2022 ($28.50 Mil) to Dec. 2023 ($30.23 Mil).

FSD Pharma Additional Paid-In Capital Historical Data

The historical data trend for FSD Pharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FSD Pharma Additional Paid-In Capital Chart

FSD Pharma Annual Data
Trend Aug15 Aug16 Aug17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only 17.37 18.79 22.58 28.50 30.23

FSD Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.50 29.63 29.83 30.20 30.23

FSD Pharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

FSD Pharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of FSD Pharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

FSD Pharma (FSD Pharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » FSD Pharma Inc (NAS:HUGE) » Definitions » Additional Paid-In Capital
Comparable Companies
TSXV:DB TSX:CWEB TSX:MDP TSXV:ZYUS XCNQ:MMEN XCNQ:CXXI XCNQ:GRIN TSX:AVNT XCNQ:ACRG.A.U XCNQ:GDNS ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
0K9:Germany HUGE:Canada
Address
199 Bay Street, Suite 4000, Toronto, ON, CAN, M5L 1A9
Website
https://www.fsdpharma.com
FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The Company operates in two segments: Biotechnology and Strategic Investments.